Computed tomographic biomarkers in idiopathic pulmonary fibrosis: the future of quantitative analysis
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease severity and rate of progression. The need for a reliable, sensitive, and objective biomarker to track disease progression and response to therapy remains a great challenge in IPF clinical trials. Over the past decade, quantitative computed tomography (QCT) has emerged as an area of intensive research to address this need. We have gathered a group of pulmonologists, radiologists and scientists with expertise in this area to define the current status and future promise of this imaging technique in the evaluation and management of IPF. In this Pulmonary Perspective, we review the development and validation of six computer-based QCT methods and offer insight into the optimal use of an imaging-based biomarker as a tool for prognostication, prediction of response to therapy, and potential surrogate endpoint in future therapeutic trials.
Date Issued
2019-01-01
Date Acceptance
2018-07-06
Citation
American Journal of Respiratory and Critical Care Medicine, 2019, 199 (1), pp.12-21
ISSN
1073-449X
Publisher
American Thoracic Society
Start Page
12
End Page
21
Journal / Book Title
American Journal of Respiratory and Critical Care Medicine
Volume
199
Issue
1
Copyright Statement
© 2018 by the American Thoracic Society.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/29986154
Subjects
biomarker
idiopathic pulmonary fibrosis
quantitative computed tomography
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2018-07-09